Skip to Content
Interactive Textbook on Clinical Symptom Research Logo


Home Button

Oral Mucositis
Author Bios
Introduction
Etiology of Oral Mucositis
Prevalence
Diagnosis
Treatment
Biological Mechanisms of Mucositis
Assessment Scale
Clinical Trial Design
Currently selected section: Population Selection and Randomization
Data Collection and Assessment Measures
Quality Control Techniques
Anaysis and Presentation
Conclusion


Chapter 17: Oral Mucositis: Clinical Trial Design for Mucositis: Population Selection and Randomization
        

During the weekly visits, adverse side effects must be documented. Adverse side effects are defined as any untoward clinical symptom, sign, or event. For instance, if the patient developed a headache and took ibuprofen for relief, this should be documented as an adverse event. All concomitant medications should be documented as well. When documenting an adverse event assess the following:

  • Onset and cessation date;
  • Frequency;
  • Severity;
  • Seriousness;
  • Relation to the study medication;
  • Action taken; and
  • Outcome.

All serious adverse events should be brought to the attention of the principal investigator and addressed immediately. Serious adverse events include any of the following:

  • Death;
  • Immediate threatening of life; and
  • Inpatient hospitalization or prolongation of existing hospitalization;
    persistent or significant disability/incapability and/or associated with congenital abnormality, cancer, or overdose.

Again, all data must correspond to the desired objectives as stated in the primary and secondary endpoints. In this study, the WHO pain ladder allows us to determine the severity and duration of mouth and throat pain, and duration of narcotic use. The WHO and OMAS scales allow us to determine the severity and duration of mucositis and the patient's oral functioning.

 

Page 16 of 21
Previous Page